Patients received either high‐intensity cytarabine‐containing remission‐induction chemotherapy (n = 36) or VEN and/or a FLT3 inhibitor (midostaurin or sorafenib [not currently approved in AML]; n = 32). The gene discussed is FLT3; the disease is acute myeloid leukemia.